Polyhexamethylene biguanide hydrochloride (PHMB)-properties and application of an antiseptic agent. A narrative review.

Acanthamoeba Antiseptic agent Keratitis Polyhexamethylene biguanide hydrochloride

Journal

European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772

Informations de publication

Date de publication:
09 Sep 2022
Historique:
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 10 9 2022
Statut: aheadofprint

Résumé

The prevention and management of ocular surface infections is still one of the great challenges for ophthalmologists. The spread of antimicrobial resistance makes it necessary to use antiseptic substances with a broad antimicrobial spectrum. Polyhexamethylene biguanide hydrochloride (Polyhexanide, PHMB) is a broad-spectrum antiseptic with excellent tolerance and a low-risk profile. Its physicochemical action on the phospholipid membrane and DNA replication or repair mechanism, prevents or impedes the development of resistant bacterial strains. PHMB revealed its effective against numerous organisms like viruses, Gram-negative and Gram-positive bacteria, and fungi. Polyhexanide is commonly used as preservative in commercially available disinfecting solutions for contact lens care and in ophthalmic formulations at different concentrations ranging from 1 µg/ml to 50 µg/ml. The administration of 0.02% (200 µg/ml) PHMB is often the first-line therapy of Acanthamoeba keratitis. However, to date, only one close-out randomized controlled study tested the efficacy of 0.02% PHMB in Acanthamoeba keratitis and a phase III study is still ongoing. This paper reviews the antiseptic agent PHMB, focusing on biochemical mechanisms, safety profile and applications in ophthalmology.

Identifiants

pubmed: 36083163
doi: 10.1177/11206721221124684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11206721221124684

Auteurs

Alfredo Niro (A)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Francesco Pignatelli (F)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Matteo Fallico (M)

Department of Ophthalmology, University of Catania, Catania, Italy.

Alessandra Sborgia (A)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Fedele Passidomo (F)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Samuele Gigliola (S)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Annalisa Nacucchi (A)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Giancarlo Sborgia (G)

Eye Clinic, Department of Medical Science, Neuroscience and Sense Organs, 9295University of Bari, Bari, Italy.

Giacomo Boscia (G)

Eye Clinic Section, Department of Surgical Sciences, 9314University of Turin, Turin, Italy.

Giovanni Alessio (G)

Eye Clinic, Department of Medical Science, Neuroscience and Sense Organs, 9295University of Bari, Bari, Italy.

Francesco Boscia (F)

Eye Clinic, Department of Medical Science, Neuroscience and Sense Organs, 9295University of Bari, Bari, Italy.

Giuseppe Addabbo (G)

Eye Clinic, Hospital "SS. Annunziata", ASL Taranto, Taranto, Italy.

Michele Reibaldi (M)

Eye Clinic Section, Department of Surgical Sciences, 9314University of Turin, Turin, Italy.

Teresio Avitabile (T)

Department of Ophthalmology, University of Catania, Catania, Italy.

Classifications MeSH